Insulet Corp.
PODD$139.30
+$6.04 (4.53%)+4.53%
ClosedInsulet cuts 2026 revenue growth guidance to 20%-22% and assumes mid-teens 2027 revenue exit rate on weaker Type 2 retention, slower new starts
Loading chart...
IndexN/A
Market Cap9.65B
Enterprise Value20.33B
Income$0.04B
Sales$0.57B
Employees3,900
P/E23.73
P/S7.38
P/B13.20
P/C52.94
EV/EBITDA38.19
EV/Sales31.27
EPS (ttm)5.87
Earnings2025-11-06
Gross Margin71.88%
Oper. Margin15.61%
Profit Margin6.22%
Volume3.25M
Shs Outstand0.07B
Change4.53%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD1.69%
Perf Year4.31%
Perf 3Y-3.75%
Perf 5Y1.14%
Perf 10Y746.67%
IPO2007-05-15
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $1.70B | $1.31B | $1.10B | $904.40M | $738.20M | $563.82M | $463.77M |
| Cost of Revenue | $625.90M | $537.20M | $499.70M | $346.70M | $322.10M | $257.90M | $193.66M | $186.60M |
| Gross Profit | $1.45B | $1.16B | $805.60M | $752.10M | $582.30M | $480.30M | $370.17M | $277.17M |
| Gross Margin | 69.79% | 68.35% | 61.72% | 68.45% | 64.39% | 65.06% | 65.65% | 59.76% |
| Operating Expenses | $1.14B | $939.90M | $768.00M | $626.10M | $530.80M | $430.30M | $342.77M | $284.57M |
| Operating Income | $308.90M | $220.00M | $37.60M | $126.00M | $51.50M | $50.00M | $27.40M | $-7.40M |
| Operating Margin | 14.91% | 12.96% | 2.88% | 11.47% | 5.69% | 6.77% | 4.86% | -1.60% |
| Net Income | $418.30M | $206.30M | $4.60M | $16.80M | $6.80M | $11.60M | $3.29M | $-26.83M |
| Net Margin | 20.19% | 12.16% | 0.35% | 1.53% | 0.75% | 1.57% | 0.58% | -5.79% |
| EPS (Basic) | $5.97 | $2.96 | $0.07 | $0.25 | $0.11 | $0.19 | $0.06 | $-0.46 |
| EBITDA | $423.70M | $323.60M | $109.00M | $139.60M | $110.30M | $74.20M | $47.10M | $6.40M |
| Stock Option Compensation Expense | $69.30M | $48.30M | $40.90M | $34.40M | $35.90M | $28.70M | $37.50M | $31.90M |
| Price To Earnings Ratio | 43.74 | 73.36 | 4439.85 | 1072.17 | 2433.56 | 894.28 | 1418.22 | -149.16 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $18.29B | $15.13B | $20.42B | $18.01B | $16.55B | $10.37B | $4.67B | $4.00B |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $3.09B | $2.59B | $2.25B | $2.05B | $1.87B | $1.14B | $928.74M | $816.74M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.88B | $1.86B | $1.77B | $1.49B | $1.27B | $1.07B | $716.64M | $658.23M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.21B | $732.70M | $476.40M | $556.30M | $603.60M | $75.90M | $212.10M | $158.52M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.21B | $732.70M | $476.40M | $556.30M | $603.60M | $75.90M | $212.10M | $158.52M |
| Total Liabilities & Stockholders Equity | $3.09B | $2.59B | $2.25B | $2.05B | $1.87B | $1.14B | $928.74M | $816.74M |
| Book Value Per Share | $17.29 | $10.50 | $6.87 | $8.22 | $9.32 | $1.25 | $3.60 | $2.73 |
| Tangible Book Value Per Share | $15.15 | $8.35 | $5.03 | $7.09 | $8.27 | $0.38 | $2.75 | $1.97 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 13.55% | 7.97% | 0.20% | 0.82% | 0.36% | 1.01% | 0.35% | -3.29% |
| Return on Equity | 34.52% | 28.16% | 0.97% | 3.02% | 1.13% | 15.28% | 1.55% | -16.93% |
| Return on Invested Capital | 11.68% | 9.66% | 0.92% | 5.58% | 2.14% | 4.05% | 2.14% | -1.01% |
| Quick Ratio | 2.73 | 2.58 | 2.61 | 4.43 | 5.21 | 3.05 | 3.31 | 5.85 |
| Current Ratio | 3.54 | 3.47 | 3.56 | 5.75 | 5.96 | 3.69 | 3.93 | 6.24 |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $418.30M | $206.30M | $4.60M | $16.80M | $6.80M | $11.60M | $3.29M | $-26.83M |
| Depreciation | $80.80M | $72.80M | $63.20M | $57.40M | $55.40M | $27.90M | $15.60M | $13.90M |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $430.30M | $145.70M | $119.00M | $-68.10M | $84.00M | $98.40M | $35.90M | $41.30M |
| Capital Expenditures | $124.90M | $75.60M | $157.30M | $122.70M | $166.50M | $170.90M | $162.35M | $77.23M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $305.40M | $70.10M | $-38.30M | $-190.80M | $-82.50M | $-72.50M | $-126.45M | $-36.02M |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers - PODDprnewswire.com ROSEN, SKILLED INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - PODDnewsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harmnewsfilecorp.com PODD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Insulet Corporation Securities Lawsuit - Contact Levi & Korsinskybusinesswire.com PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action - Contact SueWallStprnewswire.com Insulet Corporation Is Getting Closer To An Upgrade After Its Large Plungeseekingalpha.com Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More247wallst.com These Analysts Slash Their Forecasts On Insulet After Q2 Resultsbenzinga.com
Show 12 more stories
Insulet Corporation Investor Alert: Contact SBS by August 31, 2026 for Opportunity to Lead Securities Fraud Lawsuitprnewswire.com Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODDprnewswire.com Insulet Corporation (PODD) Q2 2026 Earnings Call Transcriptseekingalpha.com Insulet Q2 Earnings Call Highlightsmarketbeat.com Insulet Corp (PODD) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth Offset by Type 2 Retention Challengesgurufocus.com Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com PODD EQUITY ACTION ALERT: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026globenewswire.com Lost Money on Insulet Corporation (PODD)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinskyprnewswire.com Insulet (PODD) Beats Q2 Earnings and Revenue Estimateszacks.com Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fallreuters.com Insulet Reports Second Quarter 2026 Resultsbusinesswire.com PODD INVESTOR REMINDER: Insulet Corporation Investors Have Until August 31, 2026 To Seek Lead Plaintiff Rolebusinesswire.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Discover more
You may be interested in